SHLP2 dosage and evidence
Written by Aaron CuhaReviewed Sep 2026
The short answer
SHLP2 is a tiny peptide made by mitochondria, the power plants inside your cells. It has a known receptor, a weight result in mice, and a gene link in people to protection from Parkinson's disease. It has never been given to a person, and no trial is registered.
Evidence grade for SHLP2: Preliminary. The rule: studied in people, but no published study has had people take it. The sum on this page: 2 human studies where nobody was given it. A grade counts how much has been done to people, not whether it works.
- People given it
- 0
- Human studies
- 0
- Found nothing
- 0
Dose
No human dose established
No published study on this page has given this compound to people and reported a result.
2 human studies where nobody was given it
6 effects reported, 4 unwanted, 2 wanted, by people using it, not a trial
Goal pages: Fat loss and metabolism, Gut health
In plain English
In plain English, from Aaron
This is how I would explain it to a friend. The evidence, with the numbers, is further down the page.
SHLP2 is a short peptide your own mitochondria make and release. Think of it as a text message from the power plants in your cells. Levels drop as you get older. It has a known receptor and a real story in mice. No human being has ever been given it.
What people take it for
- Better blood sugar and insulin response.
- Fat loss, because of the mouse results.
- Protecting the eyes as they age.
- General anti aging, since the peptide falls as you get older.
What studies in people showed
There are no human trials. None. Not one person has been given this peptide in any study, and nothing is registered. In male mice, giving it protected them from getting fat on a high fat diet and improved their insulin. That result is solid and it is in mice. In cells it cut damage and helped the mitochondria work. The human side is only measuring, not giving. Levels fall with age. People who inherit a certain version of it get less Parkinson's disease. And here is the part the sales pages skip. In people without diabetes, higher levels of this peptide went along with more belly fat and more liver fat. That is the opposite direction from the mouse result. Across this whole family of peptides there is one registered human trial in the world, it is for a different one, and it will not report until 2028.
What people report
Reports, not study results
The good
- There is almost nothing to report, because so few people have access to it.
- The handful of forum reports mention more energy, which is what people report for nearly every peptide.
The bad
- No side effect profile exists, because no human has been dosed in a study.
- Anything sold under this name is a research chemical with no purity testing.
- The one human measurement runs the wrong way, which should slow you down.
- The blood tests used in these studies are off the shelf kits that nobody has independently checked.
Where these come from: The mouse and cell results are published studies. The energy reports are scattered forum posts. There are no trial exit interviews or side effect tables, because there have been no trials.
My bottom line
This is good biology and zero human evidence, and those are not the same thing. I would watch this one for another five years rather than buy it.
An opinion, not a finding. I am a coach, not a doctor.
What it has been measured to do
Measured in people
Goals SHLP2 has been tested for in people, biggest studies first. We count only what the studies on this page say, so the real numbers may be higher.
- Liver fat and liver healthno headcount stated · 1 study
Animal and lab work, not yet tested in people
Real results, but from animals or cells, not people. What works in a mouse often does not work the same way in a person. Nobody can patent this, so nobody would ever earn back the cost of a study in people. That is usually why there is none. The record on this one is set out below.
- Blood sugar and insulin2 animal or lab studies
- Eyes and vision1 animal or lab study
33 of the 36 indexed goals have no study of any kind behind SHLP2
No study in people, animals or cells on this page reports a result for these. That does not prove SHLP2 does nothing for them. It does mean anything you have heard about SHLP2 and one of these did not come from a study cited here.
Show full evidence
What is SHLP2?
SHLP2 is a tiny peptide made by mitochondria, the power plants inside your cells. It has a known receptor, a weight result in mice, and a gene link in people to protection from Parkinson's disease. It has never been given to a person, and no trial is registered.
SHLP2 is short for small humanin-like peptide 2. It has never been given to a person.
In 2016, scientists searched the same stretch of mitochondrial DNA that makes humanin, another small peptide. They found six more short peptides coded there, and named them SHLP1 to SHLP6. SHLP2 is the one with research behind it.
In people, all the evidence comes from measuring, not giving. The word to hold on to is measured. Blood levels of SHLP2 fall with age. In people without diabetes, higher SHLP2 went with more belly fat and more liver fat. Levels of this peptide family differ by race in a prostate cancer study. And some people are born with a version of SHLP2 that is linked to protection from Parkinson's disease. That is a gene link in people, not a drug effect.
The animal and lab work is better than most in this field. In rodents, SHLP2 put into the brain helped the body take up blood sugar, and stopped the liver from pushing out extra sugar. In 2023, scientists found its receptor, a switch called CXCR7. In male mice, SHLP2 given by shot or into the brain prevented weight gain on a high fat diet, and helped insulin work better. It did this through appetite nerve cells in the brain.
In a dish, SHLP2 and SHLP3 cut cell death and damage from unstable oxygen molecules. They helped mitochondria run better, and helped young fat cells mature.
Nobody has given SHLP2 to a human being. There is no registered trial. In this whole peptide family, there is exactly one registered trial anywhere in the world that gives a peptide to people. It is for MOTS-c, and it will not report before 2028.
How does SHLP2 work?
Your mitochondria have their own small set of genes. SHLP2 is made from one of them and released to act as a messenger. Its receptor, the switch it presses, is called CXCR7. In mice, SHLP2 acts on appetite nerve cells in a part of the brain called the hypothalamus, which shifts how the body balances energy. In a dish, it cuts cell death and damage from unstable oxygen molecules, and helps mitochondria run. The big idea for this whole family is that mitochondria use these peptides to tell the rest of the body how well they are working. As we age the peptides drop, so the signal gets weaker.
What have studies in people found about SHLP2?
Measuring only. SHLP2 has been measured in human blood and studied as an inborn gene version. It has never been given to a person in any published or registered study.
- Blood levels of SHLP2 fall with age, reported in the 2016 paper that named it.
- In people without diabetes, higher blood SHLP2 went with more belly fat and more liver fat.
- Blood levels of this peptide family differ by race in a prostate cancer study, reported in 2022.
- An inborn version of SHLP2 is described as protective in Parkinson's disease. That comes from a gene study, not from giving anyone the peptide.
- No study has given it to people. No registered clinical trial for SHLP2 on ClinicalTrials.gov.
What this does not tell you: Measuring a peptide and giving a peptide answer different questions. Every human finding here fits with SHLP2 just being a sign of something else. The blood finding also runs the opposite way to the mouse result, which should slow anyone down. There is a second, quieter problem. Most blood levels in this field come from store-bought test kits. Nobody outside has checked that those kits measure these peptides correctly. Irisin is the warning here: a whole field was built on test kits nobody had checked.
The state of the research
SHLP2 makes most sense as one member of a family, because the family picture is the honest one. The mitochondria peptides now include humanin and its relatives, MOTS-c, and SHLP1 to SHLP6. As of this review date, there is exactly one registered trial anywhere in the world that gives any of them to people. It is for MOTS-c, it is still signing people up, and it will not report before 2028.
Every other piece of human data in the whole family comes from measuring. Levels were checked in blood, muscle, semen or spinal fluid, then matched against age, exercise, body fat or disease. Those findings are real, and they are interesting. They are not proof that taking the peptide does anything.
Of the six SHLPs, SHLP2 has nearly all the research. SHLP1, SHLP4, SHLP5 and SHLP6 have barely been studied past the paper that named them. Anything sold or written about them is a guess based on SHLP2 and humanin.
The evidence, in charts
Fig. 1a · how many people
2studies in people cited, but none says how many people took part
number of people not stated
We do not draw a total, because none of the studies in people on this page gives one. Read the sources below for what each study measured.
We read the number of people from the source lines on this page. Where a line gives no number, we count nothing for it. We do not guess.
Fig. 1b · evidence mix
2 of 6 sources here are studies in people. The rest are not.
- Study in people · done in people233%
- Animal study · done in animals233%
- Lab (cells in a dish) · cells or tissue233%
Counted from the list of sources on this page. It counts only what we cite, so there may be more studies out there. A review counts once, however many studies it sums up.
Fig. 2 · evidence over time
The studies cover 6 different years, 2016 to 2024, counted from the list of sources on this page.
Fig. 3 · legal status at a glance
US
Not approved
UK
Not approved
AU
Not approved
CA
Not approved
Not approved in any of the four countries shown. This is what the law says, not a verdict on the science. See Legal status below for the full text and any notes.
Fig. 4 · how much does what
Nobody has tested different amounts in people
This chart would show how the effect changes as the amount goes up. For this compound, nobody has measured that in people. So we leave it empty. We will not borrow an animal chart and pretend it works the same in people.
Fig. 5 · what the molecule is
- Kind of compound
- Peptide
- Molecule weight
- About 2,500 Da for the 26 amino acid peptide.
- Half-life
- Stated in words, not a numbersee the exact wording below
- Chain length
- None on file
Half-life as stated on file: Not established in humans. No pharmacokinetic study exists because the peptide has never been dosed in a person.
No amino acid sequence is on file for SHLP2, so none is drawn rather than guessed from a name.
The studies we cite
- Study in people2021Plasma mitochondrial derived peptides MOTS-c and SHLP2 positively associate with android and liver fat in people without diabetes.
Nobody was given anything in this study. Researchers measured two peptides in the blood of people without diabetes and compared them with how much fat those people carried. The more belly fat and liver fat someone had, the higher their peptide levels ran. That is the opposite direction to the mouse work, where giving the peptide protects against weight gain. Neither finding disproves the other. Neither one can be used to predict the other.
Human plasma measurement in people without diabetes. Both MOTS-c and SHLP2 associated positively with android fat and liver fat. Worth reading carefully: the direction is positive, meaning higher peptide with more fat, which does not sit neatly with the mouse story in which giving the peptide protects against diet-induced obesity. An association in one direction and an intervention in the other are not in conflict, but neither can be used to predict the other.
- Study in people2024A naturally occurring variant of SHLP2 is a protective factor in Parkinson's disease.
Some people are born with a version of this peptide that appears to protect them from Parkinson's disease. That is the strongest human signal attached to SHLP2, and it is worth being clear about what it is. Nobody in the study was given anything. Researchers read genes and looked at who went on to develop the disease. Inheriting a helpful variant is not the same as injecting the peptide, and this work says nothing about injecting it.
Human genetics. A naturally occurring SHLP2 variant is described as protective against Parkinson's disease. This is the strongest human signal attached to the peptide and it concerns inheriting a variant, not taking a peptide. Nobody in this study was given SHLP2.
- Animal study2023Mitochondria-derived peptide SHLP2 regulates energy homeostasis through the activation of hypothalamic neurons.
In mice. Scientists found the switch SHLP2 presses, called CXCR7. Given by shot or into the brain, SHLP2 kept male mice from getting fat on a high fat diet, and helped insulin work better. It is the strongest paper on this peptide, and it is all animal work.
Identifies CXCR7 as the receptor SHLP2 binds and activates. Systemic and intracerebroventricular SHLP2 protected male mice from high fat diet induced obesity and improved insulin sensitivity, acting through POMC neurons in the arcuate nucleus. Male mice. This is the strongest mechanistic paper on the peptide and it is entirely preclinical.
- Animal study2019Metabolomic profile of diet-induced obesity mice in response to humanin and small humanin-like peptide 2 treatment.
In mice. Obese mice were given humanin or SHLP2, and scientists tracked the chemicals in their bodies. It is one of the few papers that actually gives the peptide to a living animal, rather than just measuring it.
Diet-induced obese mice treated with humanin and with SHLP2, profiled by metabolomics. Mice. Included because it is one of the few papers that actually administers the peptide to a living animal rather than measuring it.
- Lab (cells in a dish)2016Naturally occurring mitochondrial-derived peptides are age-dependent regulators of apoptosis, insulin sensitivity, and inflammatory markers.
This paper found SHLP2 and five sister peptides. In people, it only measured blood levels, and they fall with age. Nobody was given anything. In rodents, SHLP2 put into the brain helped the body handle blood sugar. In a dish, it cut cell death and cell damage, and helped mitochondria run.
The naming paper. An in silico search of the 16S rRNA region of mitochondrial DNA that encodes humanin found six more short open reading frames, SHLP1 to SHLP6. SHLP2 and SHLP3 reduced apoptosis and reactive oxygen species and improved mitochondrial metabolism in vitro and enhanced 3T3-L1 preadipocyte differentiation in culture. Rodent clamp studies showed intracerebrally infused SHLP2 increasing glucose uptake and suppressing hepatic glucose production. It also reports that circulating SHLP2 declines with age in human plasma, which is a measurement, not an intervention.
- Lab (cells in a dish)2018Characterizing the protective effects of SHLP2, a mitochondrial-derived peptide, in macular degeneration.
In a dish. Cells from the back of the eye, the kind that fail in age-related vision loss, were protected from oxygen damage. The eye claims made for this peptide go back to work at this level. No patient was involved.
Retinal pigment epithelium cell work relevant to age-related macular degeneration, reporting protective effects against oxidant injury. Cell culture. The eye claim that circulates for this peptide traces to work at this level, not to any patient.
Where to buy SHLP2
No seller we track lists SHLP2 yet. We read sellers’ public product lists every week, and this section fills in as soon as one does. Every seller, graded
Common questions
Has SHLP2 been tested in people?
Not in a completed trial cited here. 2 human studies where nobody was given it. SHLP2 is a tiny peptide made by mitochondria, the power plants inside your cells. It has a known receptor, a weight result in mice, and a gene link in people to protection from Parkinson's disease. It has never been given to a person, and no trial is registered.
What is the SHLP2 dosage?
No human dose established. No published study on this page has given this compound to people and reported a result. 2 human studies where nobody was given it
Is SHLP2 FDA-approved?
Not approved. No public filing shows it being developed as a drug, and we found no FDA permit to test it in people. It is a peptide the body makes, which can be measured in blood. It is not a product.
Has anyone taken SHLP2?
Not in any published or registered study. There is no data from giving it to people, and no registered trial. In the whole mitochondria peptide family, there is one registered trial in people, for MOTS-c. It will not report before 2028.
Does SHLP2 cause weight loss?
In people, higher blood SHLP2 goes with more belly and liver fat, which is the opposite direction. In male mice, SHLP2 given by shot or into the brain prevented weight gain on a high fat diet, and helped insulin work better. Neither of those is a weight loss result in a person.
What is the difference between SHLP2 and humanin?
They are made from the same stretch of mitochondrial DNA, and were found the same way. Humanin came first. It has more research, including studies that measured it in people. SHLP2 was one of six more peptides found in 2016, and it has its own receptor, CXCR7. Neither has been given to a person.
What about SHLP1, SHLP3, SHLP4, SHLP5 and SHLP6?
SHLP3 shows up next to SHLP2 in the first dish studies on cell death and cell damage. The rest have barely been studied past the paper that named them. If a product page says what SHLP5 does, it is guessing.
Is the Parkinson's finding a reason to take it?
No. That study found that people born with one version of SHLP2 have a lower risk of Parkinson's. Carrying a gene version for life is not the same as injecting a peptide. Nobody has tested the second one.